scholarly journals Dual‐Targeting to Cancer Cells and M2 Macrophages via Biomimetic Delivery of Mannosylated Albumin Nanoparticles for Drug‐Resistant Cancer Therapy

2020 ◽  
Vol 30 (16) ◽  
pp. 1910144
Author(s):  
Pengfei Zhao ◽  
Weimin Yin ◽  
Aihua Wu ◽  
Yisi Tang ◽  
Jinyu Wang ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Cancer Cells ◽  
Drug Resistant ◽  
M2 Macrophages ◽  
Albumin Nanoparticles ◽  
Dual Targeting

scholarly journals Dual Targeting of Cancer Cells with DARPin-Based Toxins for Overcoming Tumor Escape

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 3014 ◽  
Author(s):  
Elena Shramova ◽  
Galina Proshkina ◽  
Victoria Shipunova ◽  
Anastasia Ryabova ◽  
Roman Kamyshinsky ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Cancer Cells ◽  
Tumor Escape ◽  
Simultaneous Treatment ◽  
Repeat Proteins ◽  
Dual Targeting ◽  
Anti Cancer ◽  
Comparable Effect ◽  
Ankyrin Repeat Proteins ◽  
Pseudomonas Aeruginosa Exotoxin

We report here a combined anti-cancer therapy directed toward HER2 and EpCAM, common tumor-associated antigens of breast cancer cells. The combined therapeutic effect is achieved owing to two highly toxic proteins—a low immunogenic variant of Pseudomonas aeruginosa exotoxin A and ribonuclease Barnase from Bacillus amyloliquefaciens. The delivery of toxins to cancer cells was carried out by targeting designed ankyrin repeat proteins (DARPins). We have shown that both target agents efficiently accumulate in the tumor. Simultaneous treatment of breast carcinoma-bearing mice with anti-EpCAM fusion toxin based on LoPE and HER2-specific liposomes loaded with Barnase leads to concurrent elimination of primary tumor and metastases. Monotherapy with anti-HER2- or anti-EpCAM-toxins did not produce a comparable effect on metastases. The proposed approach can be considered as a promising strategy for significant improvement of cancer therapy.

scholarly journals Mechanism of Xu Li’s Experiential Prescription for the Treatment of EGFR-Positive NSCLC

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Bin Xu ◽  
Haitao Zhang ◽  
Yuchao Wang ◽  
Shuran Huang ◽  
Li Xu
Keyword(s):  
Lung Cancer ◽  
Cancer Cells ◽  
Small Cell ◽  
Drug Resistant ◽  
M2 Macrophages ◽  
Cellular Activity ◽  
Small Cell Lung ◽  
Associated Proteins ◽  
Egfr Tki ◽  
Resistant Cells

The non-small-cell lung cancer (NSCLC) is the most common lung cancer which seriously threatens the human health. Xu Li’s experiential prescription (XLEP) can treat the NSCLC. However, whether XLEP can regulate the autophagy in the EGFR-positive NSCLC still remains unknown. We found that the cellular activity of drug-resistant cells and sensitive cells were all decreased in the TCM group and TCM + Gef group. The expression of autophagy-associated proteins (mTOR and Beclin1-Vps34) in drug-resistant cells was decreased in the TCM group, while the expression of autophagy-associated proteins in sensitive cells was all decreased in the TCM + Gef group. The ratio of M1/M2 macrophages was increased when IL-4-induced RAW264.7 was treated with TCM. TCM treatment promoted the expression of CCL2 and CCL3 while it downregulated the CCL22 level among A549, H1975, and PC9 cells. The expression of TNF-α and IL-6 was increased, and the expression of IL-10 and TGF-β was decreased in IL-4-induced RAW264.7 cells treated with TCM. And, TCM treatment also decreased the expression of Fizz1 and TGM2. In conclusion, this study indicated that XLEP could suppress the proliferation of EGFR-TKI-resistant cancer cells and increase the ratio of M1/M2 macrophages by inhibiting autophagy to treat the drug-resistant EGFR-positive NSCLC.

scholarly journals Albendazole loaded albumin nanoparticles for ovarian cancer therapy

2014 ◽  
Vol 6 (4) ◽  
Author(s):  
Lubna Noorani ◽  
Mohammad Hossein Pourgholami ◽  
Mingtao Liang ◽  
David Lawson Morris ◽  
Martina Stenzel
Keyword(s):  
Ovarian Cancer ◽  
Cancer Therapy ◽  
Cancer Cells ◽  
Anticancer Agent ◽  
Ovarian Cancer Cells ◽  
Albumin Nanoparticles ◽  
Antiparasitic Drug ◽  
Release Studies ◽  
Uptake Studies ◽  
Low Solubility

AbstractAlbendazole (ABZ), a well-established antiparasitic drug, has been shown to suppress tumor growth in a number of preclinical models of cancer. However, the low solubility of ABZ limits its use as a systemic anticancer agent. To enable systemic administration, we have formulated ABZ into albumin nanoparticles with a size range of 200–300 nm, which were cross-linked with glutaraldehyde to stabilize the nanoparticles and to introduce pH-responsive features. Drug release studies demonstrated that about 20% of ABZ was released at neutral pH within a week in comparison to 70% at slightly acidic condition (pH 5). Cellular uptake studies using ovarian cancer cells indicated that nanoparticles were internalized efficiently within 1 h of incubation. Further, cell proliferation results demonstrated that albumin nanoparticles alone showed no cytotoxicity to both normal and cancer cells. In contrast, the drug-loaded nanoparticles exhibited cellular toxicity and high killing efficacy to cancer cells compared to normal cells. Collectively, our results suggest that these albumin nanoparticles may hold great potentials as ABZ carriers for cancer therapy.

scholarly journals Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis

2019 ◽  
Author(s):  
Xinquan Liu ◽  
Debadyuti Ghosh
Keyword(s):  
Drug Delivery ◽  
Cancer Therapy ◽  
Tumor Progression ◽  
Cancer Cells ◽  
Fluorescent Microscopy ◽  
Wild Type ◽  
Nanoparticle Delivery ◽  
Activating Mutations ◽  
Albumin Nanoparticles ◽  
Frequent Mutations

AbstractThe RAS family of oncogenes (KRAS, HRAS, NRAS) are the most frequent mutations in cancers and regulate key signaling pathways that drive tumor progression. As a result, drug delivery targeting RAS-driven tumors has been a long-standing challenge in cancer therapy. Mutant RAS activates cancer cells to actively take up nutrients, including glucose, lipids, and albumin, via macropinocytosis to fulfill their energetic requirements to survive and proliferate. Here, we exploit this mechanism to deliver nanoparticles in cancer cells harboring activating KRAS mutations. We have synthesized stable albumin nanoparticles that demonstrate significantly greater uptake in cancer cells with activating mutations of KRAS than monomeric albumin (i.e. dissociated form of clinically-used nab-paclitaxel). From pharmacological inhibition and semi-quantitative fluorescent microscopy studies, these nanoparticles exhibit significantly increased uptake in mutant KRAS cancer cells than wild-type KRAS cells by macropinocytosis. Importantly, we demonstrate that their uptake is driven by KRAS. This nanoparticle-based strategy targeting RAS-driven macropinocytosis is a facile approach towards improved delivery into KRAS-driven cancers.

Dually folate/CD44 receptor-targeted self-assembled hyaluronic acid nanoparticles for dual-drug delivery and combination cancer therapy

2017 ◽  
Vol 5 (33) ◽  
pp. 6835-6846 ◽  
Author(s):  
Liang Song ◽  
Zhou Pan ◽  
Huabing Zhang ◽  
Yanxiu Li ◽  
Yinying Zhang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Hyaluronic Acid ◽  
Cancer Therapy ◽  
Cancer Cells ◽  
Anticancer Effect ◽  
Cd44 Receptor ◽  
Dual Targeting ◽  
Combination Cancer Therapy ◽  
Self Assembled ◽  
Dual Drug

Self-assembled methotrexate-hyaluronic acid-octadecylamine nanoparticles loaded with curcumin have dual-targeting and combinational anticancer effect to folate and CD44 receptors overexpressed cancer cells.

Sign in / Sign up

Export Citation Format

Share Document